Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...

Cybin (CYBN) stock earns Guggenheim's Buy rating with a $35 target, as the firm cites blockbuster potential for CYB003 in line with J&J's (JNJ) Spravato. Read more here.

The Daily Gate mobile app brings you the latest local breaking news, updates, and more. Read the Daily Gate on your mobile device just as it appears in print.

Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant ...

POCATELLO – An Idaho State University alumnus has returned to Pocatello to address the high demand for mental health services ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Musk has said he uses ketamine regularly, so for the past couple of years, public speculation has persisted about how much he ...

Three of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, and one of RSU grants vests ratably in equal installments on the second, ...

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other psychedelic ...